Number of the records: 1  

Radiolabelled polymeric materials for imaging and treatment of cancer: Quo vadis?

  1. 1.
    0473653 - ÚMCH 2018 RIV GB eng J - Journal Article
    Pant, K. - Sedláček, Ondřej - Nadar, R. A. - Hrubý, Martin - Stephan, H.
    Radiolabelled polymeric materials for imaging and treatment of cancer: Quo vadis?
    Advanced Healthcare Materials. Roč. 6, č. 6 (2017), s. 1-31, č. článku 1601115. ISSN 2192-2640. E-ISSN 2192-2659
    R&D Projects: GA ČR(CZ) GA16-02870S; GA ČR(CZ) GA16-03156S; GA MZd(CZ) NV16-30544A; GA MZd(CZ) NV15-25781A
    Institutional support: RVO:61389013
    Keywords : polymers * cancer * radiodiagnosis
    OECD category: Pharmacology and pharmacy
    Impact factor: 5.609, year: 2017 ; AIS: 1.369, rok: 2017
    DOI: https://doi.org/10.1002/adhm.201601115

    Owing to their tunable blood circulation time and suitable plasma stability, polymer-based nanomaterials hold a great potential for designing and utilising multifunctional nanocarriers for efficient imaging and effective treatment of cancer. When tagged with appropriate radionuclides, they may allow for specific detection (diagnosis) as well as the destruction of tumours (therapy) or even customization of materials, aiming to both diagnosis and therapy (theranostic approach). This review provides an overview of recent developments of radiolabelled polymeric nanomaterials (natural and synthetic polymers) for molecular imaging of cancer, specifically, applying nuclear techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Different approaches to radiolabel polymers are evaluated from the methodical radiochemical point of view. This includes new bifunctional chelating agents (BFCAs) for radiometals as well as novel labelling methods. Special emphasis is given to eligible strategies employed to evade the mononuclear phagocytic system (MPS) in view of efficient targeting. The discussion encompasses promising strategies currently employed as well as emerging possibilities in radionuclide-based cancer therapy. Key issues involved in the clinical translation of radiolabelled polymers and future scopes of this intriguing research field are also discussed.
    Permanent Link: http://hdl.handle.net/11104/0270880
     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.